## COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

## (Present Status of Competition In the Pharmaceutical Industry)

## WEDNESDAY, MARCH 4, 1970

U.S. SENATE, SUBCOMMITTEE ON MONOPOLY OF THE SELECT COMMITTEE ON SMALL BUSINESS, Washington, D.C.

The subcommittee met, pursuant to recess, at 9:35 a.m., in room 318, Old Senate Office Building, Hon. Gaylord Nelson (Chairman of

the Subcommittee) presiding.

Present: Senators Nelson, McIntyre, and Dole.

Also present: Benjamin Gordon, Staff Economist; Elaine C. Dye,
Clerical Assistant; James P. Duffy III, Minority Counsel; and Dennison Young, Jr., Associate Minority Counsel.

Senator Nelson. Our witness today is Dr. Charles Edwards, Com-

missioner, Food and Drug Administration.

Dr. Edwards, the committee is very pleased to have you appear here today. Your statement will be printed in full in the record.

You may present it as you desire, and if you wish to extemporize from it at any time, or elaborate on it, feel free to do so.

I assume you do not mind if we interrupt with questions as you go along.

Dr. Edwards. Not at all.

Senator Nelson. All right, go ahead, Doctor.

STATEMENT OF DR. CHARLES C. EDWARDS, COMMISSIONER, FOOD AND DRUG ADMINISTRATION; ACCOMPANIED BY DR. JOHN JENNINGS, DIRECTOR, BUREAU OF MEDICINE, FOOD AND DRUG ADMINISTRATION; WILLIAM W. GOODRICH, GENERAL COUNSEL, FOOD AND DRUG ADMINISTRATION; AND DR. JOHN SCHROGIE, FOOD AND DRUG ADMINISTRATION

Dr. EDWARDS. Thank you, Senator Nelson, Senator Dole.

I would like to begin by introducing my colleagues. On my right, Dr. John Jennings, who is Director of the Bureau of Drugs, and on my left is Mr. William Goodrich, who is the general counsel for the Food and Drug Administration.

We certainly appreciate this opportunity to present to the committee the views of the Food and Drug Administration on some of the issues raised during these hearings. The primary issue, as we see